PLCB1 and glioblastoma: In analyzing data solely from GBM cases, which as a group contains the lowest PLCβ1 expression level, only subjects with top 5 % PLCβ1 expression (n = 9, mean = 25.7 months) survive significantly longer than the lower 95 % subjects (n = 142, mean = 13.2 months, p = 0.039; Fig. 6b).